1. Home
  2. ACET vs YRD Comparison

ACET vs YRD Comparison

Compare ACET & YRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

SELL

Current Price

$6.37

Market Cap

83.3M

Sector

Health Care

ML Signal

SELL

Logo Yiren Digital Ltd.

YRD

Yiren Digital Ltd.

HOLD

Current Price

$0.94

Market Cap

88.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACET
YRD
Founded
1947
2012
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
88.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
ACET
YRD
Price
$6.37
$0.94
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $34.83
N/A
AVG Volume (30 Days)
★ 272.2K
54.1K
Earning Date
11-04-2026
09-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$427.64
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$1.86
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$0.82
52 Week High
$9.97
$6.65

Technical Indicators

Market Signals
Indicator
ACET
YRD
Relative Strength Index (RSI) 34.28 39.05
Support Level N/A $0.82
Resistance Level $8.85 $1.05
Average True Range (ATR) 0.69 0.05
MACD -0.28 0.00
Stochastic Oscillator 3.45 21.43

Price Performance

Historical Comparison
ACET
YRD

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About YRD Yiren Digital Ltd.

Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.

Share on Social Networks: